Vanda Pharmaceuticals | VNDA - Pre Tax Profit


Vanda Pharmaceuticals reported $-22.92M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Esperion Therapeutics USD 63.67M 95M Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -799M 612M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Takeda JPY -52.48B 186.34B Mar/2026
Teva Pharmaceutical Industries USD 753M 662M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Veracyte USD 29.97M 10.66M Mar/2026